Adherence & outcomes of neoadjuvant immunotherapy in resectable NSCLC

Adherence & outcomes of neoadjuvant immunotherapy in resectable NSCLCПодробнее

Expert report on neoadjuvant immune checkpoint inhibitors for NSCLCПодробнее

Surgical outcomes from CheckMate 816: NIVO plus chemo vs chemo alone as neoadjuvant treatment fo...Подробнее

Advances in Immunotherapy & Resectable Non-Small Cell Lung CancerПодробнее

Improving outcomes for patients with metastatic NSCLC with immunotherapyПодробнее

Improving Outcomes in Resectable NSCLC: Decisions About Neoadjuvant and Adjuvant ImmunotherapyПодробнее

Unleashing the Potential of Perioperative Immunotherapy in Resectable NSCLCПодробнее

Neoadjuvant, Adjuvant, or Both: Individualized Perioperative Immunotherapy in Resectable NSCLCПодробнее

Clinical trials of neoadjuvant targeted therapy in resectable NSCLCПодробнее

Leveraging Neoadjuvant and Adjuvant Immunotherapy to Improve Outcomes in Early-Stage CancersПодробнее

Surgical endpoints are needed in lung cancer trials of neoadjuvant therapyПодробнее

For NSCLC Neoadjuvant Adjuvant or BothПодробнее

Perioperative therapies in NSCLCПодробнее

From concept to indication: Neoadjuvant immunotherapy for operable lung cancerПодробнее

Has Immunotherapy Brought Us to an Inflection Point in the Management of Stage I-III NSCLC?Подробнее

Results: neoadjuvant nivolumab for resectable lung cancerПодробнее

Pathologic Response After Neoadjuvant Immunotherapy: Facilitating Progress in Early-Stage CancersПодробнее

IASLC Webinar: Perioperative Treatment w/Immune Checkpoint Inhibitors in Patients w/Resectable NSCLCПодробнее

Surgical perspective on neoadjuvant IO for resectable stage III NSCLCПодробнее

Neoadjuvant and adjuvant immunotherapy in non-small cell lung cancerПодробнее